RBC Capital on Bausch & Lomb Corp. (BLCO): 'We view the delay in anticipated competition in the US Rx DED market as neutral to slightly positive'

March 17, 2026 9:36 AM

RBC Capital analyst Douglas Miehm reiterated an Outperform rating and $21.00 price target on Bausch & Lomb Corp. (NYSE: BLCO).The ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found